Novartis Poised For Growth As It Expands Its Pharma Focus And Accelerates Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
The Swiss pharma expands its areas of focus in pharmaceuticals to include dedicated units within its pharma business for respiratory, dermatology, heart failure and cell therapy, as its oncologic products continue to advance – its CDK 4/6 inhibitor will enter Phase III this year.
You may also be interested in...
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.